<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110136</url>
  </required_header>
  <id_info>
    <org_study_id>REBACCCWFU 98301</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT00110136</nct_id>
  </id_info>
  <brief_title>St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: St. John's wort may help relieve hot flashes in women with breast cancer.

      PURPOSE: This phase II trial is studying how well St. John's wort works in relieving hot
      flashes in women with non-metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the efficacy of Hypericum perforatum (St. John's wort) in alleviating hot
           flashes, in terms of hot flash frequency, score, and duration and disruption of daily
           activities caused by hot flashes, in postmenopausal women with non-metastatic breast
           cancer.

        -  Determine hot flash changes over 4 weeks in patients treated with this drug.

      Secondary

        -  Determine the toxicity of this drug in these patients.

        -  Determine the effect of Hypericum perforatum (St. John's wort) on serum tamoxifen levels
           in women receiving tamoxifen therapy.

        -  Determine the effect of Hypericum perforatum (St. John's wort) on general health-related
           quality of life and mood at 2 and 4 weeks relative to baseline, and during the 2 week
           post-treatment phase in these patients.

        -  To evaluate changes in average weekly hot flush scores and duration over course of
           study.

      OUTLINE: This is a multicenter study.

      Patients receive oral Hypericum perforatum (St. John's wort) three times daily for 4 weeks in
      the absence of disease progression or unacceptable toxicity.

      Patients complete a daily diary of the frequency, severity, and duration of their hot
      flashes, and complete quality of life and mood assessments every 2 weeks during study
      treatment and continuing weekly for 2 weeks after completion of study treatment.

      Patients receiving tamoxifen will have blood tests to measure serum tamoxifen levels at
      baseline, 2, 4, and 6 weeks.

      PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped due to concerns about interaction between St. John's wort and Tamoxifen.
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of St. John's Wort on Hot Flash Frequency as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>Primary objective was to assess the change in hot flashes over a four week period in patients given St. John's Wort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of St. John's Wort on Hot Flash Score as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>The hot flash score is calculated as the frequency of hot flashes times the severity of the hot flashes averaged over a week.
Frequency is the number of hot flashes in a day. Severity is coded 0=None, 1=Mild, 2=Moderate, and 3=Severe. Score for each day is frequency times severity. Weekly score is averaged over seven days.
Score ranges from 0 to infinity
Lower scores are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Toxicities While on St. John's Wort</measure>
    <time_frame>Six weeks following baseline (four weeks of active treatment and two weeks of follow-up)</time_frame>
    <description>Toxicities are quantified using the standard NCI toxicity criteria. The outcome is the percentage of participants who experience one or more toxicities. More detailed information on toxicities is found in the adverse events section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of St. John's Wort on Quality of Life (MCS)</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>Quality of life was measured by the SF12 (MCS and PCS subscales). First we'll summarize the MCS.
SF-12 is the short form Health Survey (a short version of the SF-36) developed for the Medical Outcomes Study. It is managed by QualityMetric.
MCS is the mental health component of the SF-12. A normal population has a mean of 50 and a SD of 10. Higher numbers represent better mental health.
The range is 0 to 100.
Higher scores represent better mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of St. John's Wort on Quality of Life (PCS)</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>Quality of life was measured by the SF12 (MCS and PCS subscales). Now we'll summarize the PCS.
SF-12 is the short form Health Survey (a short version of the SF-36) developed for the Medical Outcomes Study. It is managed by QualityMetric.
PCS is the physical health component of the SF-12. Normal population has a mean of 50 and a SD of 10. Higher scores reflect better physical health.
The range is 0 to 100.
Higher scores represent better mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood is Measured by the POMS Short Form.</measure>
    <time_frame>Baseline and four weeks</time_frame>
    <description>POMS stands for the Profile of Mood States This is a short version of the POMS (17 questions).
Each question is scored on a 0 to 4 scale. The POMS score is the sum of the responses to the 17 questions. Responses to some questions have been reversed to make higher responses better.
The range is 0 to 68.
Higher scores represent better overall mood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>St. John's Wort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient given one 300mg St. John's Wort tablet three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. John's Wort</intervention_name>
    <description>St. John's Wort 300mg tablet three times per day</description>
    <arm_group_label>St. John's Wort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Noninvasive ductal carcinoma in situ

               -  Localized breast cancer

                    -  Stage 0-IIIB disease

               -  Locally recurrent breast cancer that is post-treatment AND disease-free for ≥ 2
                  years

          -  Experiencing ≥ 3 hot flashes per day (≥ 21 per week), defined by sweating, flushing,
             sensation of warmth, night sweats, and/or rapid heart beat of sufficient severity that
             the patient desires therapeutic intervention

          -  Normal mammogram within the past 10 months

          -  Hormone receptor status:

               -  Not specified

        INCLUSION CRITERIA:

        Age

          -  18 and over

        Sex

          -  Female

        Menopausal status

          -  Post-menopausal (i.e., no menstrual periods ≥ 12 months or surgical menopause)

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin &lt; 2 mg/dL

          -  SGOT ≤ 2 times normal

        Renal

          -  Not specified

        EXCLUSION CRITERIA:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No history of intolerance to St. John's wort

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No concurrent cytotoxic chemotherapy

        Endocrine therapy

          -  No concurrent selective estrogen-receptor modulators or aromatase inhibitors (e.g.,
             anastrozole, letrozole, or exemestane) allowed

               -  Concurrent tamoxifen allowed

          -  No concurrent estrogen, progestational agents, or androgens for the alleviation of hot
             flashes

          -  No concurrent corticosteroids

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  More than 14 days since prior Hypericum perforatum (St. John's wort), monoamine
             oxidase inhibitors, selective serotonin reuptake inhibitors (e.g., sertraline,
             paroxetine, or fluoxetine) or selective norepinephrine reuptake inhibitors (e.g.,
             venlafaxine)

          -  No concurrent use of any of the following:

               -  Antidepressants

               -  Theophylline

               -  Warfarin, unless for central line prophylaxis

               -  Protease inhibitors for AIDS

               -  Digoxin

               -  Cyclosporine

               -  Benzodiazepines (e.g., diazepam or alprazolam)

               -  Calcium-channel blockers (e.g., diltiazem or nifedipine)

               -  Coenzyme A reductase inhibitors for serum cholesterol reduction

               -  Macrolide antibiotics (e.g., azithromycin, erythromycin, or clarithromycin)

               -  Griseofulvin

               -  Phenobarbital

               -  Phenytoin

               -  Rifampin

               -  Rifabutin

               -  Grapefruit juice

               -  Other naturopathic or herbal products

               -  Ketoconazole

               -  Fluconazole

               -  Itraconazole

               -  Rifabutin

          -  No other concurrent medications for the alleviation of hot flashes (e.g., clonidine or
             bellamine)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Naughton, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center at Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Howard University Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Beaumont</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Louis-Cape Girardeau</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hugh Chatham Memorial Hospital</name>
      <address>
        <city>Elkin</city>
        <state>North Carolina</state>
        <zip>28621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center at ECU Medical School</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27835-6028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Cancer Specialists</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29925</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <results_first_submitted>September 4, 2014</results_first_submitted>
  <results_first_submitted_qc>December 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2014</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was open between 3/16/2006 and 4/1/2008. The nine patients were accrued between 11/06 and 2/08.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>St. John's Wort</title>
          <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All registered participants are used in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>St. John's Wort</title>
          <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of St. John's Wort on Hot Flash Frequency as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks</title>
        <description>Primary objective was to assess the change in hot flashes over a four week period in patients given St. John's Wort</description>
        <time_frame>Baseline and four weeks</time_frame>
        <population>All registered participants</population>
        <group_list>
          <group group_id="O1">
            <title>St. John's Wort</title>
            <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of St. John's Wort on Hot Flash Frequency as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks</title>
          <description>Primary objective was to assess the change in hot flashes over a four week period in patients given St. John's Wort</description>
          <population>All registered participants</population>
          <units>number of occurrences</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of the change in hot flash frequency from baseline to four weeks; null hypothesis is no change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2629</p_value>
            <p_value_desc>Paired t-test; no adjustments for multiple comparisons</p_value_desc>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>The difference is post minus pre so negative values represents fewer hot flashes after treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of St. John's Wort on Hot Flash Score as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks</title>
        <description>The hot flash score is calculated as the frequency of hot flashes times the severity of the hot flashes averaged over a week.
Frequency is the number of hot flashes in a day. Severity is coded 0=None, 1=Mild, 2=Moderate, and 3=Severe. Score for each day is frequency times severity. Weekly score is averaged over seven days.
Score ranges from 0 to infinity
Lower scores are better.</description>
        <time_frame>Baseline and four weeks</time_frame>
        <population>All registered participants</population>
        <group_list>
          <group group_id="O1">
            <title>St. John's Wort</title>
            <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of St. John's Wort on Hot Flash Score as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks</title>
          <description>The hot flash score is calculated as the frequency of hot flashes times the severity of the hot flashes averaged over a week.
Frequency is the number of hot flashes in a day. Severity is coded 0=None, 1=Mild, 2=Moderate, and 3=Severe. Score for each day is frequency times severity. Weekly score is averaged over seven days.
Score ranges from 0 to infinity
Lower scores are better.</description>
          <population>All registered participants</population>
          <units>frequency times severity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Assessment of the change in the hot flash score over time</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1365</p_value>
            <p_value_desc>Paired t-test; unadjusted for multiple comparisons.</p_value_desc>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.37</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.45</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>Difference in hot flash score is post minus pre so a negative value represents a decrease in the frequency and/or severity of the hot flashes.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of Toxicities While on St. John's Wort</title>
        <description>Toxicities are quantified using the standard NCI toxicity criteria. The outcome is the percentage of participants who experience one or more toxicities. More detailed information on toxicities is found in the adverse events section.</description>
        <time_frame>Six weeks following baseline (four weeks of active treatment and two weeks of follow-up)</time_frame>
        <population>All registered participants</population>
        <group_list>
          <group group_id="O1">
            <title>St. John's Wort</title>
            <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of Toxicities While on St. John's Wort</title>
          <description>Toxicities are quantified using the standard NCI toxicity criteria. The outcome is the percentage of participants who experience one or more toxicities. More detailed information on toxicities is found in the adverse events section.</description>
          <population>All registered participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="29.93" upper_limit="92.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of St. John's Wort on Quality of Life (MCS)</title>
        <description>Quality of life was measured by the SF12 (MCS and PCS subscales). First we'll summarize the MCS.
SF-12 is the short form Health Survey (a short version of the SF-36) developed for the Medical Outcomes Study. It is managed by QualityMetric.
MCS is the mental health component of the SF-12. A normal population has a mean of 50 and a SD of 10. Higher numbers represent better mental health.
The range is 0 to 100.
Higher scores represent better mental health.</description>
        <time_frame>Baseline and four weeks</time_frame>
        <population>All registered participants.</population>
        <group_list>
          <group group_id="O1">
            <title>St. John's Wort</title>
            <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of St. John's Wort on Quality of Life (MCS)</title>
          <description>Quality of life was measured by the SF12 (MCS and PCS subscales). First we'll summarize the MCS.
SF-12 is the short form Health Survey (a short version of the SF-36) developed for the Medical Outcomes Study. It is managed by QualityMetric.
MCS is the mental health component of the SF-12. A normal population has a mean of 50 and a SD of 10. Higher numbers represent better mental health.
The range is 0 to 100.
Higher scores represent better mental health.</description>
          <population>All registered participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Assess the change in MCS from baseline to four weeks in patients receiving St. John's wort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8320</p_value>
            <p_value_desc>Paired t-test; unadjusted for multiple comparisons.</p_value_desc>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>5.92</ci_upper_limit>
            <estimate_desc>This is the change in MCS from baseline to four weeks (post minus pre) so values greater than zero reflect improvement in QOL.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of St. John's Wort on Quality of Life (PCS)</title>
        <description>Quality of life was measured by the SF12 (MCS and PCS subscales). Now we'll summarize the PCS.
SF-12 is the short form Health Survey (a short version of the SF-36) developed for the Medical Outcomes Study. It is managed by QualityMetric.
PCS is the physical health component of the SF-12. Normal population has a mean of 50 and a SD of 10. Higher scores reflect better physical health.
The range is 0 to 100.
Higher scores represent better mental health.</description>
        <time_frame>Baseline and four weeks</time_frame>
        <population>All registered participants.</population>
        <group_list>
          <group group_id="O1">
            <title>St. John's Wort</title>
            <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of St. John's Wort on Quality of Life (PCS)</title>
          <description>Quality of life was measured by the SF12 (MCS and PCS subscales). Now we'll summarize the PCS.
SF-12 is the short form Health Survey (a short version of the SF-36) developed for the Medical Outcomes Study. It is managed by QualityMetric.
PCS is the physical health component of the SF-12. Normal population has a mean of 50 and a SD of 10. Higher scores reflect better physical health.
The range is 0 to 100.
Higher scores represent better mental health.</description>
          <population>All registered participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Assess the change in PCS from baseline to four weeks; null hypothesis is no change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9995</p_value>
            <p_value_desc>Paired t-test on the change in PCS from baseline to four weeks; unadjusted for multiple comparisons.</p_value_desc>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.71</ci_lower_limit>
            <ci_upper_limit>5.71</ci_upper_limit>
            <estimate_desc>This is the change in PCS from baseline to four weeks (post minus pre), so positive numbers represent improvement in QOL.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mood is Measured by the POMS Short Form.</title>
        <description>POMS stands for the Profile of Mood States This is a short version of the POMS (17 questions).
Each question is scored on a 0 to 4 scale. The POMS score is the sum of the responses to the 17 questions. Responses to some questions have been reversed to make higher responses better.
The range is 0 to 68.
Higher scores represent better overall mood.</description>
        <time_frame>Baseline and four weeks</time_frame>
        <population>All registered participants.</population>
        <group_list>
          <group group_id="O1">
            <title>St. John's Wort</title>
            <description>Patients given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
          </group>
        </group_list>
        <measure>
          <title>Mood is Measured by the POMS Short Form.</title>
          <description>POMS stands for the Profile of Mood States This is a short version of the POMS (17 questions).
Each question is scored on a 0 to 4 scale. The POMS score is the sum of the responses to the 17 questions. Responses to some questions have been reversed to make higher responses better.
The range is 0 to 68.
Higher scores represent better overall mood.</description>
          <population>All registered participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Assess the change in mood from baseline to four weeks. Null hypothesis is no change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1042</p_value>
            <p_value_desc>Paired t-test; unadjusted for multiple comparisons.</p_value_desc>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.35</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>9.822</ci_upper_limit>
            <estimate_desc>This is the change in mood from baseline to four weeks (post minus pre). Mood is scored so that higher numbers represent better mood so positive changes represent an improvement in mood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Ten weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>St. John's Wort</title>
          <description>Patient given one 300mg St. John's Wort tablet three times per day
St. John's Wort: St. John's Wort 300mg tablet three times per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensiivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Prutitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was stopped early due to concerns about the interaction between St. John's wort and tamoxifen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Doug Case</name_or_title>
      <organization>Wake Forest CCOP Research Base</organization>
      <phone>(336) 716-1048</phone>
      <email>dcase@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

